Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following H1 receptor antagonists does not have an active metabolite?

Mizolastine. ### Explanation The correct answer is **Mizolastine**. **1. Why Mizolastine is the correct answer:** Mizolastine is a second-generation H1 receptor antagonist [2] characterized by its unique metabolic profile. Unlike many other antihistamines in its class [1], Mizolastine is primarily metabolized in the liver via **glucuronidation** and oxidation into **inactive metabolites**. It does not rely on the formation of an active metabolite to exert its therapeutic effect, which contributes to its predictable pharmacokinetics and lower potential for drug-drug interactions compared to those requiring CYP450 activation. **2. Why the other options are incorrect:** * **Loratadine:** It is a prodrug that is extensively metabolized by CYP3A4 and CYP2D6 into its potent active metabolite, **Desloratadine** [1, 2]. * **Azelastine:** This phthalazinone derivative [2] is metabolized into an active metabolite, **Desmethylazelastine**, which contributes to its long duration of action. * **Ebastine:** It is a prodrug that undergoes near-complete first-pass metabolism by CYP3A4 to form its active metabolite, **Carebastine**. **3. NEET-PG High-Yield Clinical Pearls:** * **Active Metabolite Pairs:** Remember the pairs for exams: Terfenadine → Fexofenadine; Loratadine → Desloratadine; Ebastine → Carebastine; Hydroxyzine → Cetirizine [1, 2]. * **Mizolastine Unique Features:** It has a dual mechanism —it blocks H1 receptors and also inhibits the release of inflammatory mediators (like leukotrienes) from mast cells. * **Safety Note:** Unlike its predecessors (Terfenadine and Astemizole), Mizolastine has a significantly lower risk of causing Torsades de Pointes (QT prolongation), though caution is still advised with potent CYP3A4 inhibitors.

Q: Atracurium is metabolized and excreted by?

Hoffman's elimination. **Explanation:** **Atracurium** is a benzylisoquinolinium neuromuscular blocking agent (NMBA) unique for its metabolic pathway. Unlike most drugs that rely on organ-based clearance, Atracurium undergoes **Hofmann elimination**. **1. Why Hofmann Elimination is Correct:** Hofmann elimination is a **non-enzymatic, spontaneous chemical degradation** that occurs at physiological pH and temperature. The drug breaks down into inactive metabolites (primarily laudanosine and quaternary monoacrylate). Because this process is independent of organ function, Atracurium is the **drug of choice for patients with renal or hepatic failure.** Additionally, it undergoes metabolism by **non-specific plasma esterases** (distinct from pseudocholinesterase). **2. Why Other Options are Incorrect:** * **Kidney (A) & Liver (B):** While most NMBAs (like Vecuronium or Rocuronium) depend on hepatic metabolism or renal excretion, Atracurium’s primary route is organ-independent. This makes it safer in multi-organ dysfunction syndrome (MODS). * **Brain (C):** The brain does not serve as a site for drug metabolism or excretion for NMBAs. In fact, NMBAs are polar compounds that do not cross the blood-brain barrier. **High-Yield Clinical Pearls for NEET-PG:** * **Cisatracurium:** An isomer of Atracurium that also undergoes Hofmann elimination but is more potent and produces less **laudanosine**. * **Laudanosine Toxicity:** A metabolite of Atracurium that can cross the blood-brain barrier; in high concentrations, it may act as a CNS stimulant and trigger **seizures**. * **Histamine Release:** Atracurium can trigger mast cell degranulation, potentially causing hypotension, flushing, and bronchospasm. * **Temperature/pH Sensitivity:** Since Hofmann elimination is spontaneous, the rate of degradation increases with **hyperthermia** and **alkalosis**, and decreases with hypothermia and acidosis.

Q: A patient has a serum creatinine of 150-300 micromol/L. Which of the following drugs requires dosage reduction?

Gentamycin. **Explanation** The core concept tested here is the **renal clearance of drugs**. A serum creatinine of 150–300 µmol/L indicates significant renal impairment (normal range: 60–110 µmol/L). Drugs that are primarily excreted unchanged by the kidneys and have a narrow therapeutic index require mandatory dose adjustment in such patients to prevent toxicity. **Why Gentamycin is Correct:** Gentamycin is an aminoglycoside that is almost exclusively excreted by glomerular filtration. It is highly nephrotoxic and ototoxic. In renal failure, its half-life increases significantly, leading to accumulation. Therefore, dosage reduction (either by decreasing the dose or increasing the dosing interval) is mandatory, often guided by Therapeutic Drug Monitoring (TDM). **Analysis of Incorrect Options:** * **Ampicillin & Penicillin:** While these are primarily excreted by the kidneys, they have a **wide therapeutic index**. Dose adjustment is generally only required in severe renal failure (Creatinine Clearance < 10–30 ml/min). At the creatinine levels provided, they are relatively safe. * **Isoniazid:** This drug is primarily metabolized by the **liver** via acetylation. Its clearance is not significantly affected by renal impairment; thus, it does not require routine dose reduction in this patient. **NEET-PG High-Yield Pearls:** * **Ames Rule:** Aminoglycosides (Gentamycin, Amikacin) always require dose adjustment in renal failure. * **Drugs avoided in renal failure:** Tetracyclines (except Doxycycline), Nitrofurantoin, and NSAIDs. * **Safe in renal failure:** Ceftriaxone, Doxycycline, Erythromycin, and Warfarin (primarily hepatic clearance). * **Formula:** For drugs like Gentamycin, the "Interval Rule" is often used: *New Interval = Normal Interval × (Patient's Creatinine / Normal Creatinine).*

Q: What is the half-life of alteplase?

6 minutes. **Explanation:** **Alteplase (rt-PA)** is a recombinant form of human tissue plasminogen activator. The correct answer is **6 minutes** (Option B). The pharmacokinetics of alteplase are characterized by a very rapid clearance from the plasma, primarily mediated by the liver. It follows a biphasic elimination pattern: the initial dominant half-life is approximately **4 to 6 minutes**, while the terminal half-life is longer (around 40 minutes). In the context of NEET-PG, the initial half-life is the standard value tested, as it dictates the clinical administration of the drug (loading bolus followed by a continuous infusion). **Analysis of Options:** * **Option A (3 mins):** Too short; while clearance is rapid, the distribution phase takes slightly longer. * **Option C & D (9 & 12 mins):** These values exceed the established initial half-life of alteplase. Drugs like **Reteplase** (13–16 mins) and **Tenecteplase** (20 mins) have longer half-lives, allowing for bolus dosing without prolonged infusion. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Alteplase is "clot-specific"; it preferentially activates plasminogen bound to fibrin, limiting systemic fibrinogenolysis compared to Streptokinase. * **Dosing:** Due to the short 6-minute half-life, it must be given as an **IV bolus followed by an infusion** to maintain therapeutic levels. * **Antidote:** In cases of severe bleeding, **Epsilon-aminocaproic acid** or **Tranexamic acid** can be used as inhibitors of fibrinolysis. * **Comparison:** Tenecteplase is the most fibrin-specific and has the longest half-life among the group.

Q: Which of the following drugs does NOT exhibit first-pass metabolism?

Salicylates. ### Explanation **Concept: First-Pass Metabolism** First-pass metabolism (presystemic elimination) is the phenomenon where a drug is metabolized in the gut wall or liver before reaching the systemic circulation. This significantly reduces the bioavailability of orally administered drugs. **Why Salicylates is the Correct Answer:** Salicylates (such as Aspirin) are rapidly absorbed from the stomach and upper small intestine. While they undergo metabolism in the liver, they do **not** undergo significant first-pass metabolism that limits their systemic availability. They have high oral bioavailability (approx. 70–100%). In contrast, the other options are classic examples of drugs with high first-pass extraction. **Analysis of Incorrect Options:** * **Nitroglycerine (B):** This drug has the highest first-pass metabolism (nearly 100%). This is why it is administered sublingually to bypass the liver and reach the coronary arteries immediately. * **Morphine (A):** Morphine undergoes extensive glucuronidation in the liver. Its oral dose is significantly higher than its parenteral dose due to this high first-pass effect. * **Propranolol (C):** A classic example of a drug with high hepatic extraction. Only about 25% of an oral dose reaches the systemic circulation. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for High First-Pass Metabolism:** "**L**ive **N**ightly **P**roperly **M**eta **I**s **S**o **H**ard" (**L**ignocaine, **N**itroglycerine, **P**ropranolol, **M**orphine, **I**mipramine, **S**albutamol, **H**ydrocortisone). * **Routes to bypass first-pass:** Sublingual, Transdermal, and Rectal (partial bypass—lower 1/3rd of the rectum). * **Bioavailability ($F$):** For IV administration, $F = 100\%$. For drugs with high first-pass metabolism, $F$ is significantly low.

Q: Which drug is administered as a racemic mixture of two enantiomers with different pharmacokinetic and pharmacodynamic properties?

Verapamil. **Explanation:** **Verapamil** is a classic example of a drug administered as a **racemic mixture** where the two enantiomers exhibit distinct properties. * **Pharmacodynamics:** The **L-isomer (S-verapamil)** is significantly more potent (10–20 times) as a calcium channel blocker compared to the D-isomer (R-verapamil). * **Pharmacokinetics:** Verapamil undergoes stereoselective first-pass metabolism. The L-isomer is metabolized more rapidly than the D-isomer. This explains why oral doses of verapamil must be much higher than intravenous doses to achieve the same therapeutic effect, as the more active L-isomer is heavily cleared by the liver before reaching systemic circulation. **Analysis of Incorrect Options:** * **A. Dilantin (Phenytoin):** This is an achiral molecule (it does not have a chiral center) and therefore does not exist as enantiomers. It is known for its zero-order kinetics at high therapeutic doses. * **B. Digoxin:** This is a complex steroid glycoside derived from the foxglove plant. While it has multiple chiral centers, it is purified as a single natural stereoisomer, not a racemic mixture. * **D. Octreotide:** This is a synthetic cyclic octapeptide (somatostatin analogue). It consists of specific L- and D-amino acids in a fixed sequence, but it is not administered as a racemic mixture of two mirror-image molecules. **NEET-PG High-Yield Pearls:** * **Other Racemic Mixtures:** Warfarin, Ketamine, and Ibuprofen. * **Single Enantiomers:** Some drugs are developed as single isomers to reduce side effects (e.g., **Levocetirizine** from Cetirizine, **Esomeprazole** from Omeprazole, and **S-Amlodipine**). * **Clinical Note:** The stereoselective metabolism of Verapamil is a frequent exam topic regarding the "First Pass Effect."

Q: Which of the following does not affect the metabolism of theophylline?

Steroids. Theophylline is a methylxanthine with a narrow therapeutic index, primarily metabolized by the hepatic **Cytochrome P450 (CYP1A2)** enzyme system. Its clearance is highly sensitive to drugs or lifestyle factors that induce or inhibit these enzymes.### Explanation of Options* **Steroids (Correct Answer):** Corticosteroids (like Prednisolone or Dexamethasone) do not significantly induce or inhibit the CYP1A2 enzymes responsible for theophylline metabolism. While they are often co-prescribed with theophylline in asthma/COPD management for their anti-inflammatory effects, they do not necessitate a dose adjustment of theophylline.* **Erythromycin:** This is a potent **enzyme inhibitor**. It inhibits CYP1A2, leading to decreased clearance of theophylline, increased plasma levels, and potential toxicity (nausea, arrhythmias, seizures) [1].* **Smoking:** Tobacco smoke contains polycyclic aromatic hydrocarbons which act as **enzyme inducers** (specifically CYP1A2). Chronic smokers metabolize theophylline much faster than non-smokers, often requiring higher doses to achieve therapeutic effects.* **Cimetidine:** A well-known non-specific **CYP450 inhibitor**. It significantly reduces theophylline clearance, increasing the risk of toxicity [1].### High-Yield Clinical Pearls for NEET-PG1. **Narrow Therapeutic Index:** The therapeutic range for theophylline is **10–20 µg/mL**. Toxicity often manifests above 20 µg/mL.2. **Other Important Inhibitors (Increase levels):** Ciprofloxacin, Clarithromycin, Allopurinol, and Oral Contraceptive Pills (OCPs).3. **Other Important Inducers (Decrease levels):** Phenytoin, Rifampicin, Phenobarbitone, and Carbamazepine.4. **Zero-Order Kinetics:** At high/toxic concentrations, theophylline metabolism can shift from first-order to zero-order kinetics, making levels rise unpredictably.

Q: Elimination after 3 half-lives in first-order kinetics is:

87.50%. ### Explanation **1. Understanding the Correct Answer (87.50%)** In **First-Order Kinetics**, a constant *fraction* of the drug is eliminated per unit of time. This means that with every half-life ($t_{1/2}$), the concentration of the drug remaining in the plasma is reduced by exactly 50%. To calculate the amount eliminated, we track the amount **remaining** first: * **After 1 $t_{1/2}$:** 50% remains (50% eliminated). * **After 2 $t_{1/2}$:** 50% of 50% = 25% remains (75% eliminated). * **After 3 $t_{1/2}$:** 50% of 25% = **12.5% remains**. To find the total amount eliminated: $100\% - 12.5\% = \mathbf{87.5\%}$. **2. Analysis of Incorrect Options** * **A. 12.50%:** This represents the amount of drug **remaining** in the body after 3 half-lives, not the amount eliminated. * **B. 75%:** This is the amount eliminated after **2 half-lives**. * **D. 94%:** This is the approximate amount eliminated after **4 half-lives** (specifically 93.75%). **3. NEET-PG High-Yield Pearls** * **Steady State:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration ($C_{ss}$) during constant drug administration, and similarly 4 to 5 half-lives to completely eliminate a drug (>95%) after stopping it. * **First-Order vs. Zero-Order:** Most drugs follow first-order kinetics. In **Zero-Order kinetics** (e.g., Ethanol, high-dose Aspirin, Phenytoin), a constant *amount* (not fraction) is eliminated, and the concept of a fixed half-life does not apply. * **Formula for Half-life:** $t_{1/2} = 0.693 \times V_d / CL$. Note that half-life is independent of the dose in first-order kinetics.

Question 1

Which of the following H1 receptor antagonists does not have an active metabolite?

Accepted Answer

Mizolastine

Answer

Loratidine

Answer

Azelastine

Answer

Ebastine

Question 2

Atracurium is metabolized and excreted by?

Accepted Answer

Hoffman's elimination

Answer

Kidney

Answer

Liver

Answer

Brain

Question 3

A patient has a serum creatinine of 150-300 micromol/L. Which of the following drugs requires dosage reduction?

Accepted Answer

Gentamycin

Answer

Ampicillin

Answer

Isoniazid

Answer

Penicillin

Question 4

What is the half-life of alteplase?

Accepted Answer

6 minutes

Answer

3 minutes

Answer

9 minutes

Answer

12 minutes

Question 5

Which of the following drugs does NOT exhibit first-pass metabolism?

Accepted Answer

Salicylates

Answer

Morphine

Answer

Nitroglycerine

Answer

Propranolol

Question 6

Which drug is administered as a racemic mixture of two enantiomers with different pharmacokinetic and pharmacodynamic properties?

Accepted Answer

Verapamil

Answer

Dilantin

Answer

Digoxin

Answer

Octreotide

Question 7

Esmolol is a short-acting beta-blocker because:

Accepted Answer

Its plasma hydrolysis by esterases is rapid.

Answer

It has more plasma protein binding.

Answer

It has high lipid solubility.

Answer

It has high oral bioavailability.

Question 8

Which of the following does not affect the metabolism of theophylline?

Accepted Answer

Steroids

Answer

Erythromycin

Answer

Smoking

Answer

Cimetidine

Question 9

Drug X is normally administered at a rate of 50mg/hr. The elimination of Drug X from the body occurs via: Hepatic metabolism 10%, Biliary secretion 10%, Renal excretion 80%. This drug is to be administered to a 65-year-old patient with a GFR of 60 ml/min (assuming normal GFR is 120 ml/min). Liver and biliary functions are normal in the patient. What will be the dose rate of Drug X in this patient?

Accepted Answer

75mg/hr

Answer

50mg/hr

Answer

25mg/hr

Answer

100mg/hr

Question 10

Elimination after 3 half-lives in first-order kinetics is:

Accepted Answer

87.50%

Answer

12.50%

Answer

75%

Answer

94%

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?